Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Deborah Shultz

General Practice Tampa, FL Medical Doctor

NPI 1154341014 CMS profile 51615

15320 Amberly Dr Ste A, Tampa, FL 33647

Open in the dashboard

General payments

$3,880

233 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Deborah Shultz of Tampa, FL is reported in the CMS Open Payments database as having received $3,880 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $64 4
2021 General $1,354 69
2020 General $1,128 69
2019 General $1,333 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Shultz
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Deborah Shultz were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Deborah Shultz General Practice median Middle half National median
2019 $1,333 $107 $37–$285 $163
2020 $1,128 $75 $25–$213 $114
2021 $1,354 $93 $30–$272 $132
2022 $64 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $890 57 payments
  2. Amgen Inc. $374 26 payments
  3. GlaxoSmithKline, LLC. $286 20 payments
  4. Merz North America, Inc. $274 1 payment
  5. AbbVie, Inc. $267 17 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $249 16 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $230 14 payments
  8. Merck Sharp & Dohme Corporation $215 16 payments
  9. Janssen Pharmaceuticals, Inc $178 11 payments
  10. Astellas Pharma US Inc $111 8 payments
  11. Other $806 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,865 231 payments
  2. Education $16 2 payments
Products named General payments · program years 2019–2022
  1. FARXIGA $622 39 payments
  2. AIMOVIG $365 25 payments
  3. Repatha $345 24 payments
  4. XIFAXAN $230 14 payments
  5. TRELEGY ELLIPTA $222 14 payments
  6. JANUMET $215 16 payments
  7. JANUVIA $215 16 payments
  8. SYMBICORT $193 14 payments
  9. XARELTO $178 11 payments
  10. STEGLATRO $174 13 payments
  11. Other $2,513 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

263

Median for General Practice: 1,105

Drug cost

$2,667

Median for General Practice: $48,734

Branded share of claims

4.2%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 54 $451
Albuterol Sulfate Hfa Albuterol Sulfate Brand 11 $402
Gabapentin Generic 21 $308
Levothyroxine Sodium Generic 22 $217
Cefdinir Generic 12 $211
Fluticasone Propionate Generic 15 $205
Atorvastatin Calcium Generic 19 $166
Omeprazole Generic 14 $163
Rosuvastatin Calcium Generic 21 $150
Metformin Hcl Generic 17 $112

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$4,877

Of which drugs: $61

Medicare patients

64

Average age 74

Services billed

543

36 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Chronic kidney disease 34%
Ischemic heart disease 33%
Diabetes 30%
Depression 25%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record